Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027960 (
mole
)
21,279
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
V
2
O
5
, one of the earliest intercalation-type cathode materials investigated as a Li
+
host, is characterized by an extremely high theoretical capacity (441 mAh g
-1
). However, the fast capacity fading upon cycling in conventional
carbonate
-based electrolytes is an unresolved issue. Herein, we show that using a LiTFSI/tetraglyme (1:1 in
mole
ratio) electrolyte yields a highly enhanced cycling ability of V
2
O
5
(from 20% capacity retention to 80% after 100 cycles at 50 mA g
-1
within 1.5-4.0 V vs Li
+
/Li). The improved performance mostly originates from the V
2
O
5
electrode itself, since refreshing the electrolyte and the lithium electrode of the cycled cells does not help in restoring the V
2
O
5
electrode capacity. Electrochemical impedance spectroscopy (EIS), post-mortem scanning electron microscopy (SEM), energy-dispersive X-ray (EDX) spectroscopy, and X-ray photoelectron spectroscopy (XPS) have been employed to investigate the origin of the improved electrochemical behavior. The results demonstrate that the enhanced cyclability is a consequence of a thinner but more stable cathode-electrolyte interphase (CEI) layer formed in LiTFSI/tetraglyme with respect to the one occurring in 1 M LiPF
6
in EC/DMC (1:1 in weight ratio, LP30). These results show that the cyclability of V
2
O
5
can be effectively improved by simple electrolyte engineering. At the same time, the uncovered mechanism further reveals the vital role of the CEI on the cyclability of V
2
O
5
, which can be helpful for the performance optimization of vanadium-oxide-based batteries.
...
PMID:Cathode-Electrolyte Interphase in a LiTFSI/Tetraglyme Electrolyte Promoting the Cyclability of V
2
O
5
. 3321 45
<< Previous
1
2
3
4
5
6
7
8
9
10
